Millennium Management LLC Makes New Investment in Tenax Therapeutics, Inc. (NASDAQ:TENX)

Millennium Management LLC acquired a new stake in Tenax Therapeutics, Inc. (NASDAQ:TENX) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 26,809 shares of the specialty pharmaceutical company’s stock, valued at approximately $166,000.

Separately, Janus Henderson Group PLC bought a new stake in Tenax Therapeutics in the fourth quarter valued at about $1,026,000. 1.67% of the stock is currently owned by institutional investors.

Tenax Therapeutics Trading Up 1.9%

Shares of Tenax Therapeutics stock opened at $5.85 on Friday. The stock has a market capitalization of $24.27 million, a price-to-earnings ratio of -2.36 and a beta of 1.61. The firm’s 50-day moving average price is $5.76 and its two-hundred day moving average price is $6.06. Tenax Therapeutics, Inc. has a 1-year low of $2.77 and a 1-year high of $7.89.

Tenax Therapeutics (NASDAQ:TENX) last announced its earnings results on Wednesday, May 14th. The specialty pharmaceutical company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.20. As a group, equities research analysts predict that Tenax Therapeutics, Inc. will post -0.88 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Guggenheim restated a “buy” rating and set a $15.00 price target on shares of Tenax Therapeutics in a research note on Thursday, May 15th. Leerink Partners set a $20.00 target price on Tenax Therapeutics in a report on Monday, March 10th. Wall Street Zen began coverage on Tenax Therapeutics in a research note on Friday, May 16th. They issued a “sell” rating on the stock. Finally, William Blair reiterated an “outperform” rating on shares of Tenax Therapeutics in a research note on Monday, March 10th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $17.50.

Tenax Therapeutics Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.